NOCIL Limited has formally announced a board meeting scheduled for May 7, 2026, to approve its audited financial results for the financial year ended March 31, 2026. The company issued an official intimation on April 9, 2026, to both the Bombay Stock Exchange and National Stock Exchange of India, fulfilling regulatory requirements under SEBI guidelines.

Board Meeting Details

The meeting will convene on Thursday, May 7, 2026, at the company's registered office located at Mafatlal House, 4th Floor, Backbay Reclamation, Mumbai 400 020. The board will deliberate on multiple critical agenda items related to the company's annual financial performance and shareholder returns.

Key Agenda Items

The board meeting will address several important matters concerning the company's financial performance and future distributions. The primary focus will be on reviewing and approving the comprehensive financial statements that reflect the company's performance during FY26.

The key items for consideration include:

• Approval of audited standalone financial results for FY26
• Approval of audited consolidated financial results for FY26
• Review of audit reports accompanying the financial statements
• Consideration of dividend payment on equity shares for FY26

Regulatory Compliance

The intimation was issued in compliance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which mandates listed companies to inform stock exchanges about board meetings at least two clear days before the meeting date. The official communication was signed by Amit K. Vyas, Head-Legal & Company Secretary, and digitally authenticated on April 9, 2026.

The company has notified both major stock exchanges where its shares are listed, ensuring full transparency and regulatory adherence in its corporate governance practices.

NOCIL Limited has reached a significant milestone in its capacity enhancement project at the Dahej facility, announcing the commencement of trial batches for rubber chemicals production. The company made this disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Project Background and Investment

The trial batch commencement follows NOCIL's earlier announcement regarding its substantial investment in capacity enhancement. The company had disclosed capital expenditure not exceeding ₹250 crore specifically allocated towards expanding rubber chemicals production capacity at its Dahej facility.

Current Development Status

The company has successfully initiated trial batches at the facility, marking a crucial phase in the project timeline. According to the official communication, the trial process involves multiple stages designed to ensure product quality and customer satisfaction.

The operational framework includes:

• Conducting comprehensive trial runs
• Sample preparation and quality assessment
• Customer sample distribution for approval
• Evaluation and feedback collection

Next Phase and Commercial Production

NOCIL has indicated that following the trial runs, samples will be sent to customers for approval processes. This customer validation phase represents a critical step before full-scale commercial operations can commence. The company has committed to providing separate intimation regarding the commencement of commercial production once the trial phase concludes successfully.

Strategic Significance

This capacity enhancement project at Dahej represents NOCIL's continued focus on expanding its rubber chemicals business. The substantial investment of up to ₹250 crore demonstrates the company's commitment to strengthening its market position and meeting growing demand in the rubber chemicals sector. The successful initiation of trial batches indicates progress toward achieving the project's operational objectives.